The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.
Age 18 years or older
Meet possible or probable CBS criteria
Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)
Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome
Subjects will be excluded if they have a mutation in the progranulin gene
Subjects will excluded if they have received anti-Aβ therapy
All patients who meet criteria are eligible to participate
Case-control
Prospective
C-11 ER176 Radiotracer
Diagnostic testPET scan looking for inflammation
C-11 PiB
Diagnostic testPET scan looking for amyloid protein
AV1451 Tau
Diagnostic testPet scan looking for Tau protein
The investigators will use C-11 ER176 PET imaging to evaluate neuroinflammation and white matter integrity in CBS
Measure whether regional patterns of ER176-PET uptake and white matter microstructure abnormalities using NODDI differ between CBS-4R, CBS-AD, Amn-AD, and HC.
the investigators will use blood samples to assess inflammatory and tau blood plasma metrics in CBS.
Measure whether plasma metrics differ between CBS-4R, CBS-AD, Amn-AD, and HC.
The investigators will use MR imaging to compare regional markers of inflammation, white matter integrity and tau burden in autopsy tissue from patients with CBS from two different 4R tauopathies and CBS-AD.
Click on the lead sponsor to view all of their trials.
Jennifer Whitwell
Lead sponsor
Mayo Clinic
Sponsor institution
National Institute on Aging (NIA)
Collaborator
